Effects of Cabergoline administration on uterine perfusion in women with polycystic ovary syndrome

Objectives: The aim of this study was to determine the effects of Cabergoline administration on uterine bloodflowinwomensufferingfrompolycysticovarysyndrome�(PCOS). Methods:�Thisstudyisarandomized,�controlled,�triple-blindtrialwhichistestedon�40�womenwhowere� randomlydividedintotwogroupsof�20�peopleandusingarandomized block design during which the subjects were assessed and included. They were suffering from polycystic ovarian syndrome. Inclusion criteria were classicallydefinedPCOScriteriaincluding:�oligomenorrheaoramenorrhea,�clinicalorLaboratoryfindings� basedonincreaseinbloodlevelandrogen�(testosterone)�andultrasoundconfirmationofPCOS.��Exclusion� criteria were Pregnancy, lactation, Dopamine Agonist Therapy. After selection of intervention and placebo groups, primary control Doppler ultrasound was done for both groups. Then a weekly dose of Cabergoline 0.5�mgwasadministeredtointerventiongroupfordurationof�12�weeks.�Placebogroupwereadministered� placebo in the same fashion. At the end of 12 weeks, Doppler ultrasound was performed and the results were recorded in the check lists. Results:�Nosignificantdifferencewasnoticedinbothgroupswithrespecttotheirage,�employment,�level� ofeducation,�typeofinfertility,�durationofmarriage,�andresultsofRIandPIbeforeintervention.�Later� PCOSpatientsunderthetreatmentofCabergolineshowedasignificantincreaseinuterinebloodflow� PulsatilityIndex�(PI)�before�2.65±0.52�andafter�1.98±0.52�andRIbefore�0.85�andafterintervention�0.77),� yetnosignificantdifferencewerefoundinPCOSpatientunderthetreatmentofplacebo. Conclusion:�PCOSpatientswereshowntohavemoreresistanceinuterinebloodflowthanhealthypeople;� however, Cabergoline administration proved to increase uterine blood perfusion and regulate menstruation cycle. KEYWORD:� Polycysticovariansyndrome,� Cabergoline,� Uterinearteryresistance,� ResistanceIndex,� PulsatilityIndex.